Charles Rowland Elected to BIND Therapeutics Board of Directors

posted in: News | 0

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced that at BIND’s annual meeting of stockholders held today the company’s stockholders elected Mr. Charles A. Rowland, Jr., CPA, most recently the … Continued

BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes of Lead Cancer Drug Candidate, BIND-014, at AACR 2014 Annual Meeting

posted in: News | 0

BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today that clinical data on its lead drug candidate, BIND-014, were presented at the American Association of Cancer Research (AACR) meeting. The … Continued

Twist Bioscience secures $26M Series B and $5.1M from DARPA

posted in: News | 0

Twist Bioscience today announced that it raised $26 million in a Series B financing to commercialize the company’s semiconductor-based synthetic gene manufacturing process. Nick and Joby Pritzker, through their family’s firm Tao Invest, led the round, with participation from ARCH … Continued

ARMO BioSciences Closes $30 Million Series B Financing

posted in: News | 0

ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced it raised $30 million in a Series B private financing led by NanoDimension. Existing investors Kleiner Perkins Caufield & Byers, OrbiMed and DAG Ventures also participated in the round. “This financing … Continued

Crocus licenses MLU™ technology to ARM

posted in: News | 0

Crocus Technology, a leading developer of magnetically enhanced semiconductor technologies for mobile security, embedded microcontrollers, harsh environment electronics and magnetic sensors, today announces it has licensed its Magnetic Logic Unit™ (MLU™) technology to ARM®. Magnetic Logic Unit™ (MLU) is a … Continued